As the Chief Medical Officer and co-founder of Geneoscopy, I am passionate about transforming gastrointestinal health through cutting-edge RNA diagnostics. My mission is to develop non-invasive, accessible, and highly effective screening and monitoring tools to detect diseases like colorectal cancer and inflammatory bowel disease (IBD) early—when intervention can make the biggest impact.

Under my leadership, Geneoscopy’s ColoSense became the first FDA-approved RNA-based test for colorectal cancer screening in average-risk patients. We’ve raised over $200M in funding, built a 24,000 sq. ft. CAP/CLIA laboratory, and launched commercial efforts in partnership with Labcorp to make this life-saving technology widely available. As we continue expanding our diagnostic solutions, our goal is to usher in a new era of personalized medicine for gastrointestinal health.

Beyond my role at Geneoscopy, I am a physician-scientist with an MD and a PhD in Bioinformatics from Washington University School of Medicine. My research has led to 30+ peer-reviewed publications, four book chapters, and multiple patents in the precision medicine space. I was also honored to be named to Forbes 30 Under 30 for my contributions to healthcare innovation.